Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma

Highlights • Empirical antibiotic treatment approach is accepted for infection diseases before cultures and antibiograms are available. • Oncologic patients requiring intensive care support are usually excluded from clinical trials. • Empirical erlotinib treatment can be reasonable in critical patie...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2014-10, Vol.86 (1), p.102-104
Main Authors: Bosch-Barrera, Joaquim, Sais, Elia, Lorencio, Carol, Porta, Rut, Izquierdo, Angel, Menéndez, Javier A, Brunet, Joan, Sirvent, Josep Maria, Rosell, Rafael
Format: Article
Language:English
Subjects:
Adenocarcinoma - diagnosis
Adenocarcinoma - drug therapy
Adenocarcinoma - pathology
Adenocarcinoma of Lung
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Critically ill patient
EGFR mutation
Erlotinib
Erlotinib Hydrochloride
Female
Hematology, Oncology and Palliative Medicine
Humans
Intensive care unit
Intensive Care Units
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Mechanical ventilation
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Nasogastric tube
Neoplasm Metastasis
Non-small-cell lung cancer
Pneumology
Protein Kinase Inhibitors - therapeutic use
Pulmonary/Respiratory
Quinazolines - therapeutic use
Respiration, Artificial
Tomography, X-Ray Computed
Treatment Outcome
Tumors
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Empirical antibiotic treatment approach is accepted for infection diseases before cultures and antibiograms are available. • Oncologic patients requiring intensive care support are usually excluded from clinical trials. • Empirical erlotinib treatment can be reasonable in critical patients with lung cancer when an EGFR mutation is suspected. • This case report shows that erlotinib administration through nasograstic tube is effective in this setting. • Some clinically selected patients could get benefit from empirical erlotinib treatment as part of an ICU trial.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2014.07.010